Results: Endocrine therapy (ET) was used in 404/2061 (20%) patients. Median age of patients treated with compared with without ET, was 53 versus 57 years, (P < 0.0005). One of 417 (0.2%) versus 399/1548 (26%) patients took ET before versus after NSABP-B24. Among the post-Allred era cohort treated with ET (N = 227), tumors were ER-positive in 65%, ER-negative in 1%, and ER-unknown in 33%; whereas of those treated without ET (N = 801), ER was positive in 43%, negative in 15%, and unknown in 42% (P < 0.0005). On multivariable analysis of the post-NSABP-B24 era, ET was associated with improved event-free survival (EFS) (hazard ratio 0.6; P = 0.02); 5-year EFS were 96.9% with ET versus 94.5% without ET.
introduction
In 1999, the National Surgical Adjuvant Breast and Bowel Project (NSABP) B24 randomized trial demonstrated a benefit with the addition of tamoxifen to radiotherapy (RT) after breast-conserving surgery (BCS) for women with ductal carcinoma in situ (DCIS) [1] . In 1999, our institution changed the provincial policy concerning the use of tamoxifen for patients with DCIS, and tamoxifen was approved for public funding. In June 2001, Cuzick et al. showed that tamoxifen did not reduce breast cancer events in DCIS patients treated with RT + BCS [2] [3] [4] . In December 2002, Allred reported a subgroup analysis of NSABP-B24 showing the benefit of tamoxifen mainly applied to those with estrogen receptor (ER)-positive disease [5, 6] . Since 2002, our institution has recommended that 5 years of tamoxifen be considered for DCIS depending on risk factors, particularly age and margin status, after confirmation of ER positivity (unless life expectancy is <10 years or there are tamoxifen contraindications) [7] .
After clinical trials establish a benefit, observational studies are essential to identify whether practice has changed appropriately and whether the expected outcomes are achieved in a general population [8] . Some studies have investigated tamoxifen use in women with DCIS, but none has addressed the issue specifically in those treated with BCS + RT [9] [10] [11] [12] . Since our institution is the single provider of RT and ET in the province, it allows us to examine this question on an unselected population of a defined geographic region.
Our primary objective was to determine the impact and generalizability of the NSABP-B24 study and ER subgroup analysis at a population level. Secondary objectives were to assess the degree to which the trial results [1, 4, 5] were incorporated into clinical practice, and the ET continuation rates in patients with DCIS treated with BCS + RT.
methods
The study was approved by the University of British Columbia (BC)/BC Cancer Agency Research Ethics Board. A total of 2061 women diagnosed with pure DCIS between 1 January 1989 and 31 December 2009 treated with BCS and RT were analyzed. Patients with contralateral DCIS, microinvasion, mixed or second histologies, synchronous invasive breast cancer, and previous invasive cancer (except nonmelanoma skin cancer) before, or at diagnosis of DCIS were excluded.
The study population was limited to those treated with BCS + RT because the objective was to determine the impact and generalizability of the NSABP-B24 trial. Data were abstracted from the prospectively collected provincial Breast Cancer Outcomes Unit database. Surgical margins were categorized as positive if tumor was touching ink and negative if tumor did not touch ink. ER status testing is described in the supplementary Material, available at Annals of Oncology online.
Linkage was carried out with the provincial pharmacy database to obtain ET information on all patients. Adjuvant ET was defined as tamoxifen or aromatase inhibitor started within 1 year of initial diagnosis in the absence of progression, relapse, or second primary cancer. If adjuvant ET was prescribed, a 5-year course was recommended at the outset, but not all patients who started ET completed a 5-year course (see ET Adherence section of the Results). Pharmacy data obtained included dates on which each prescription was filled and the corresponding number of pills dispensed.
The primary end point was event-free survival (EFS), defined as freedom from local, regional, distant recurrence, and contralateral noninvasive and invasive breast cancer. Ipsilateral event-free survival (IEFS) was defined as freedom from local and regional noninvasive and invasive breast cancer.
To examine ET utilization and evaluate the benefit of ET, the following cohorts were analyzed: (1) pre-NSABP-B24 era (all patients diagnosed from 1989 to 1998, N = 417); (2) post-NSABP-B24 era (all patients diagnosed from 2000 to 2009, N = 1548). The later cohort was further subdivided into pre-and post-Allred eras (i.e. before and after 2003). Patients diagnosed in 1999 and 2003 were excluded from the defined eras to account for the dissemination periods of NSABP-B24 [1] and ER subgroup analysis [5] results, respectively.
Continued use of ET was analyzed using Kaplan-Meier methods, with patients censored at the development of noninvasive or invasive breast cancer, last follow-up, or at death. The date of ET discontinuation was the last day covered by a dispensed ET prescription. Patients who had at least 80% of the days of the intended 5-year ET period covered by a filled prescription were considered adherent [4] .
statistical analysis
Oncologic outcomes including EFS, IEFS, breast cancer-specific survival (BCSS), and overall survival (OS) were calculated using Kaplan-Meier methods and compared using log-rank tests. On univariable analysis (UVA), clinicopathologic characteristics were compared among patients treated with versus without ET using χ 2 tests for categorical variables and t-tests for continuous variables. Cox regression modeling was used for UVA and multivariable analyses (MVA) of EFS, IEFS, and OS. All variables in the UVA were included in the MVA, for which a backwards selection process was used until all remaining variables in the model had P < 0.1. Statistical significance was established at P ≤ 0.05. Statistical Package for the Social Sciences, version 14.4 (Chicago, IL) was used for analyses.
results
Median follow-up was 9 years (range, 7 months to 24 years) for the entire cohort, 16 years for the pre-NSABP-B24 era (range, 1-24 years), and 8 years (range, 7 months to 13 years) for the post-NSABP-B24 era. Median age at diagnosis was 56 years.
Patients receiving ET were more likely to be younger, premenopausal, and have ER+ tumors (Table 1) .
ET utilization
Overall, 400 women took tamoxifen (20 mg), 1 took anastrozole (1 mg) because of history of deep vein thrombosis, and 3 were started on tamoxifen but switched to anastrozole 3-9 months later due to intolerance to tamoxifen (flare of arthritis, thrombophlebitis, and nausea).
In the pre-NSABP-B24 era, 1 of 417 patients (0.2%) took ET, whereas in the post-NSABP-B24 era, 399 of 1548 patients (26%) took ET. The utilization of ET by year is shown in Figure 1 , along with the rates of ER assessment. In the years after the NSABP-B24 trial, the initial utilization of ET was higher, up to almost 50%, reflecting partial incorporation of the trial findings into practice. ET use then decreased after presentation of the Cuzick abstract. After release of the Allred abstract, the rates of ER assessment increased, as did the use of ET, which then stabilized at ∼20%.
Characteristics of the ET versus no ET group were compared and contrasted for the post-NSABP-B24 era and the post-Allred ER+ group (Table 2) . Patients receiving ET were younger and were more often premenopausal. Among patients receiving ET in the post-Allred era (N = 227), tumors were ER+ in 65%, ER− in 1%, and ER-unknown in 33%, whereas of those who did not receive ET (N = 801), ER was positive in 43%, negative in 15%, and unknown in 42% (P < 0.0005). In comparing the post-NSABP pre-Allred era to the post-Allred era, ET use significantly decreased from 31% (4/13) to 2% (3/123) in ER− tumors (P < 0.0005), and from 39% (141/358) to 19% (76/409) in ERunknown tumors (P < 0.0005); ET use increased from 19% (5/26) to 30% (148/496) in ER+ tumors, but this difference was not significant (P = 0.25), and the proportion of ER-unknown tumors decreased over the intervals.
ET and oncological outcomes for the post-NSABP-B24 era
For the post-NSABP-B24 era, oncological outcomes stratified by ET use are displayed in Table 3 . EFS, IEFS, and OS were significantly higher in patients who received ET, but BCSS was equivalent. Table 4 summarizes the UVA and MVA of EFS and IEFS. ET and negative margins were associated with higher EFS and IEFS. Compared with ER-negative disease, ER-positive and ER-unknown diseases were associated with higher IEFS, but had no significant impact on EFS.
On MVA of OS, age at diagnosis [hazard ratio (HR) 1.1; 95% confidence interval (CI) 1.06-1.11; unit = 1 year] and tumor size (HR 1.02; 95% CI 1.01-1.04; unit = 0.1 cm) were significant on MVA, but not ET use (HR 0.6; 95% CI 0.3-1.05). Among the 5% (75/1548) of patients who died, 1% (14/1548) were due to breast cancer. In the ET group, 0.6% (1/164) of patients died of uterine cancer, compared with 0.5% (4/739) in the non-ET group.
ET adherence
Of the 404 patients who started ET, 1-and 4-year KaplanMeier rates of continuation were 76% and 55%, respectively. Median time on ET was 4.5 years. Of the 362 patients who were not censored by 5 years after the start of ET, 175 (48%) patients had ≥80% of the days of the 5-year period covered by a filled prescription, and were therefore considered adherent.
discussion
This study demonstrates that the NSABP-B24 trial exerted a significant impact on clinical practice in BC. Due to findings of the trial, ET utilization increased after publication of NSABP-B24, and in relation to Allred's subgroup analysis, younger age and ER+ status were significantly associated with administration of ET. Furthermore, the impact of ET per NSABP-B24 is confirmed at a population level, with ET being associated with Previous studies have reported on patterns of tamoxifen use in DCIS, but included all DCIS patients instead of focusing on BCS+RT [9] [10] [11] [12] . Two smaller monoinstitutional studies demonstrated that factors associated with tamoxifen use were BCS, smaller tumors [9] , and ER positivity [10] . A multi-institutional study showed that receipt of tamoxifen increased after presentation of NSABP-B24 but varied substantially by institution [11] . A Surveillance, Epidemiology and End-results (SEER) analysis showed that tamoxifen use decreased from 36% in 2000 to 21% in 2005 [12] . In an Italian study of low-dose tamoxifen, which included all patients with ductal intraepithelial neoplasia (DIN) treated with surgery, women were more likely treated with tamoxifen if they were younger and premenopausal, or had tumors that contained necrosis or were hormone receptor positive [13] .
In the current study, the utilization of ET increased significantly after the publication of NSABP-B24 in 1999. After the release of Allred's abstract demonstrating a clear reduction in ipsilateral and contralateral events with tamoxifen in ER+ tumors [5] , the use of ET initially increased to ∼30%, while ER assessment was still being carried out in the minority of patients. As the rates of ER assessment increased, ET utilization became more selective, and stabilized at ∼20%. Consistent with the aforementioned Italian study and the NSABP-B24 findings, a greater proportion of younger and premenopausal patients were prescribed ET in our study. Since the publication of Allred's abstract [5] , the majority of patients in our study who received ET had ER+ disease.
To our knowledge, this is the first population-based study investigating the benefit of ET specifically in DCIS managed with BCS + RT. Consistent with NSABP-B24, our analysis showed that ET was associated with improved EFS and IEFS. The NSABP-B24 and the current results differed from the Cuzick trial which reported that tamoxifen did not reduce breast cancer events in those receiving BCS + RT; however, accounting for the greater benefit of ET on younger DCIS patients [1] , this contrasting result is likely related to the smaller proportion of women under 50 (9.5%) in the Cuzick trial, compared with ∼30% in NSABP-B24 and the current study. While the relative benefit of ET was similar between our study and NSABP-B24, the 5-year event rates were lower in our study (3% with ET and 7% without ET) than in NSABP-B24 (8% and 13%, respectively). This difference could be related to differences in the rate of margin positivity, which was 5% in our cohort, and 16% in NSABP-B24. Supporting this notion, the stipulation of negative margins is a possible reason that the event rate was even lower in Cuzick (3% in patients receiving RT, with or without tamoxifen).
Consistent with the NSABP-B24 and Cuzick trials, the current study found that ET did not improve BCSS. OS was higher in the ET group, but this is likely related to the younger age of this group, given that ET was not associated with improved OS on MVA, and BCSS was equivalent with or without ET.
Patient adherence to ET is an important issue, as worse outcomes have been demonstrated with <5 years of treatment in invasive breast cancer [14] [15] [16] [17] [18] , and with early discontinuation of tamoxifen in DIN [13] . Multiple methods have been used to estimate ET adherence, including patient self-report, physician report, pill count, microelectronic monitoring, and pharmacy and claims data. As some studies have suggested that patient and physician reports overestimate adherence [19, 20] , others have relied on pharmacy and claims-based data instead [21] [22] [23] . While ET adherence is well-reported in invasive disease, our study is among the few to examine ET adherence in DCIS, and is the only study that uses pharmacy records rather than physician or self-report.
In the adherence analysis in Yen et al.'s DCIS study, 65 of 94 patients (69%) who started tamoxifen were still taking it at a median follow-up of 13 months [9] . Accounting for the actuarial method that we used to calculate ET continuation, our continuation rates were similar to that demonstrated by Yen (76% at 1 year, and 55% at 4 years). By comparison, the Italian study on DIN reported higher actuarial rates of tamoxifen continuation: 96% at 1 year and 73% at 5 years in premenopausal women, and 94% and 70%, respectively, in postmenopausal women. Possible reasons for their higher adherence rates include the utilization of physician report, the lower dose of tamoxifen (5 mg per day) which might have resulted in less toxicity, a larger proportion of patients on clinical trials, and referral bias since the study was not population-based. In BC, ET adherence among patients with lowrisk invasive cancer has been documented at 53% [24] . Using the same pharmacy database and methodology for calculating adherence, our study indicates that ET adherence among women with DCIS is similar, at 48% over a 5-year period.
The main limitations of our study are inherent biases of the retrospective design. Although we controlled for several factors in the MVA of IEFS and EFS, it is possible that other factors were unbalanced between groups due to lack of randomization. For example, we were unable to account for margins and comedonecrosis, which were not consistently recorded. However, the provincial pathology guidelines recommend Van Nuys grading incorporating both nuclear grade and comedonecrosis [25] ; which was equally balanced between the ET and no ET groups. In addition, although ER status was included on MVA, this variable may not have been adequately controlled for due to the high proportion of ER-unknown disease. Lastly, while pharmacy data are more accurate than patient or physician report for ET adherence, it is less accurate than manual pill counts or microelectronic monitoring.
conclusions
This study demonstrates that the NSABP-B24 trial had a clear impact on ET utilization in DCIS patients treated with 
